• linkedin
  • Increase Font
  • Sharebar

    Bladder Cancer: Androgen receptor activation a potential therapeutic target

    Byron H. Lee, MD, PhDByron H. Lee, MD, PhDMultiple studies on exosomes, data from the IMvigor 210 trial of atezolizumab (TECENTRIQ), and research on prehabilitation for cystectomy were among the highlights in bladder cancer from the 2016 AUA annual meeting. The take-home messages for bladder cancer were presented by Byron H. Lee, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York.   

    Richard R. Kerr
    Kerr is group content director for Urology Times.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available